EGFR and neoplasm: However, SCLC transformation and tumor heterogeneity have never been reported in sequential targeted therapy and immunotherapy.<h4>Case presentation</h4>Here, we described a patient with advanced EGFR-mutant NSCLC, who received erlotinib and underwent the resistance with EGFR T790M (-).